Analyzing Dominari (NASDAQ:DOMH) and Lotus Pharmaceuticals (OTCMKTS:LTUS)

Dominari (NASDAQ:DOMH) and Lotus Pharmaceuticals (OTCMKTS:LTUS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Insider & Institutional Ownership

42.5% of Dominari shares are held by institutional investors. 29.9% of Dominari shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Dominari and Lotus Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dominari	1	0	0	0	1.00
Lotus Pharmaceuticals	0	0	0	0	0.00

Profitability

This table compares Dominari and Lotus Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dominari	110.86%	-50.80%	-44.80%
Lotus Pharmaceuticals	N/A	N/A	N/A

Risk and Volatility

Dominari has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Comparatively, Lotus Pharmaceuticals has a beta of -1.69, suggesting that its stock price is 269% less volatile than the S&P 500.

Earnings and Valuation

This table compares Dominari and Lotus Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dominari	$18.15 million	3.25	-$14.70 million	$5.57	0.65
Lotus Pharmaceuticals	N/A	N/A	$110,000.00	N/A	N/A

Lotus Pharmaceuticals has lower revenue, but higher earnings than Dominari.

Summary

Dominari beats Lotus Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

About Dominari

Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.

About Lotus Pharmaceuticals

Lotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee.